Press Releases



 
Press Releases
  Date Title View
Dec 9, 2016
REDWOOD CITY, Calif., Dec. 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies demonstrating the unparalleled value of the Oncotype DX® test in individualizing breast cancer treatment decisions for patients with various stages of the disease. Presentations included two overviews of prospect...
PDF
Nov 29, 2016
REDWOOD CITY, Calif., Nov. 29, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present seven Oncotype DX® studies at the 39th CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), which is being held December 6-10, 2016. The study findings reinforce the Company's leadership in individualizing breast cance...
PDF
Nov 3, 2016
REDWOOD CITY, Calif., Nov. 3, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, chief operating officer and chief financial officer, will present at the Credit Suisse 25th Annual Healthcare Conference in Scottsdale, Arizona on Tuesday, November 8, 2016 at 3:30 p.m. Mountain Time. To access the live and...
PDF
Nov 1, 2016
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended September 30, 2016. Total revenue was $82.3 million in the third quarter of 2016, compared with $73.6 million in the third quarter of 2015, an increase of 12 percent. U.S. ...
PDF
Nov 1, 2016
REDWOOD CITY, Calif., Nov. 1, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced topline results from a large clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study, performed in collaboration with a large integrated healthcare system, met its primary endpoint by demonstr...
PDF
Oct 26, 2016
REDWOOD CITY, Calif., Oct. 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced publication in Reviews in Urology of a comprehensive economic analysis of the use of the Oncotype DX® Genomic Prostate ScoreTM (GPS) in low-risk prostate cancer patients. Results showed that use of the GPS results in a net savings of $2,286 ...
PDF
Oct 25, 2016
REDWOOD CITY, Calif., Oct. 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, November 1 at 4:30 p.m. Eastern Time to discuss its third quarter 2016 financial results. The call and webcast will follow the release of the third quarter financial results aft...
PDF
Oct 11, 2016
REDWOOD CITY, Calif., Oct. 11, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from its successfully completed analytical validation study of Oncotype SEQ™ Liquid Select, which demonstrated that this liquid biopsy mutation panel is highly sensitive, specific and reproducible. To provide transparent and clinica...
PDF
Oct 10, 2016
REDWOOD CITY, Calif., Oct. 10, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from eight Oncotype DX® Breast Recurrence Score™ (RS) presentations at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, highlighting superior clinical evidence in identifying which patients...
PDF
Sep 28, 2016
REDWOOD CITY, Calif., Sept. 28, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from nine studies at the European Society for Medical Oncology (ESMO) 2016 Congress, which will take place October 7-11 at the Bella Center in Copenhagen, Denmark. The results will include: Analyt...
PDF
1
...
NextLast